Kerry Holtham’s Post

📅 Add this to your 2024 calendar! 📅    Returning to Boston in July, the 4th Induced Proximity-Based Drug Discovery Summit will unite 100+ small molecule and biologics experts in the race to develop new stabilization, modulation, post-translational modification and inactivation/activation modalities for novel target spaces.  So, if your excited about DUBTACs, curious about PHICS, caught up on AUTOTACs or invested in the development of molecular glues or induced proximity biologics don't miss out on hearing the latest developments and innovations from Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, PAQ Therapeutics, Rapafusyn Pharmaceuticals, EpiBiologics, Gandeeva Therapeutics, Vicinitas Therapeutics, Novartis, Genentech, Dana-Farber Cancer Institute, Lyterian Therapeutics, Broad Institute of MIT and Harvard, AstraZeneca, Solu Therapeutics, AUTOTAC BIO Inc., Kronos Bio, Goethe University Frankfurt, Nurix Therapeutics, and many more! To explore all expert-led talks, view the 2024 Agenda here:  👉 https://lnkd.in/ec3JYh_q 👈  #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC

📣 Calling all DUBTAC, CyTAC, EpiTAC, PHICS and Molecular Glue Fanatics 📣 The long established 4th Induced Proximity-Based Drug Discovery Summit is returning to Bostin this July 23-25, 2024, to explore the emerging proximity phenomenon!! Check out the official event guide here 👉https://lnkd.in/er2TX2Bu Taking on knowledge gaps in validating novel mechanisms of action, accessing diverse chemical matter, and rationally designing selective and potent small molecules and biologics for novel target spaces, hear first-hand from pioneering leaders at Vicinitas Therapeutics, Gandeeva Therapeutics, Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, Rapafusyn Pharmaceuticals, Dana-Farber Cancer Institute, AstraZeneca, Genentech, AUTOTAC BIO Inc., Goethe University Frankfurt, Nurix Therapeutics, Kronos Bio, Solu Therapeutics, Broad Institute of MIT and Harvard, Lyterian Therapeutics, PAQ Therapeutics, EpiBiologics, Novartis and many more! To explore all expert-led talks, view the 2024 Agenda here👉https://lnkd.in/eNmryrhm 👈 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC

Hope everyone had a great week! I wanted to share some of this weeks Life Science Industry Highlights: Apollomics updated their strategic focus and announced key leadership changes, aiming to streamline operations and prioritize their lung cancer trials. Cerus welcomed Dean Gregory Gregory to their Board of Directors, bringing in new expertise to drive forward their mission. Mendel.ai unveiled a groundbreaking neuro-symbolic AI system, outperforming GPT-4 in a new study for automatic cohort retrieval. Semnur Pharmaceuticals, Inc., a subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) signed a letter of intent for a proposed business combination. Adicet Bio, Inc Bio received FDA Fast Track Designation for ADI-270 in metastatic/advanced clear cell renal cell carcinoma, accelerating the development of this promising treatment. AusperBio highlighted major advances in the clinical development of AHB-137. Biostar Pharmaceuticals Inc Pharma got FDA clearance for an IND application for a Phase 2 study of Utidelone Injection (UTD1) in HER2- breast cancer brain metastasis. CellProthera SAS and BioCardia, Inc. successfully collaborated on a Phase II trial of ProtheraCytes for treating acute myocardial infarction. #Biotech #Pharma #LifeScience #HealthcareInnovation #AIinHealthcare #ClinicalTrials #FDAApproval #Biopharma #LifeSciences #MedicalResearch #DrugDevelopment #HealthTech #Biotechnology #Pharmaceuticals #BiotechNews #Innovation #Healthcare #MedTech #ResearchAndDevelopment

💊 🔬 Join KCAS Bio for an enlightening webinar as we explore the expanding role of hybrid LC-MS/MS in ADC analysis. Discover how this innovative approach offers flexibility and multiple advantages, allowing for the simultaneous monitoring of total antibodies and ADCs, irrespective of conjugation type or linker used. From oncology to novel modalities like antibody-peptide conjugates and antibody-RNA conjugates (ARCs), hybrid LC-MS/MS is reshaping the landscape of drug development. Don't miss this opportunity to gain insights from Dawn Dufield into the transformative potential of hybrid LC-MS/MS and enhance your bioanalytical capabilities. ➡️ REGISTER HERE: https://buff.ly/4aMa6wF #DrugDevelopment #Biosimilars #Bioanalytical #MassSpectrometry #LaboratoryTechnology #LiquidChromatography #BioanalyticalTesting

If you are working on a biologic therapy for a #neurodegenerative disease or #stroke, consider registering for the upcoming #Blueprint #Neurotherapeutics for biologics (BPN-Biologics) Q&A webinar on Oct. 23 at 2pm ET. This would include biotechnology products and biologics-based therapies such as peptides, proteins, and antibodies, gene-based therapies such as oligonucleotide and viral based cell therapies, as well as other novel emerging therapies including microbial and microbiome therapies. #BPNBiologics provides #nondilutive funding and resources for drug discovery and development, from lead optimization through phase I clinical testing. Investigators interested in learning about the program can register here: https://lnkd.in/ezN-_r-U

Check out our latest paper titled "T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics" published by Mabs! The immunogenicity of biologics is predominantly shaped by the landscape of T and B cell epitopes, yet it remains challenging to visualize these critical hotspots. In this article, we succinctly outlined the recent advancements in techniques for identifying immunogenic epitopes. Moreover, we underscored the significance of understanding epitope profiles in guiding the deimunization of antibodies as well as other types of therapeutic proteins. Many thanks to my co-authors Mark Qian and Xiaobin Zhang for their invaluable contributions to this work!

Unlocking New Possibilities in Precision Medicine The world of pharmaceuticals is evolving rapidly, and one of the most exciting breakthroughs is the rise of Antibody-Drug Conjugates (ADCs). ADCs are an innovative class of targeted therapy that combines the precision of monoclonal antibodies with the potent effects of cytotoxic drugs. 🔬 Targeted Delivery: ADCs work by selectively delivering toxic drugs to cancer cells, sparing healthy cells. This targeted approach enhances efficacy while minimizing side effects, leading to better patient outcomes. 💡 Versatility and Adaptability: ADCs offer a flexible platform that can be tailored for different types of cancers and diseases. This adaptability opens up new avenues for personalized medicine, allowing for more precise treatment plans. 💼 Business Impact: For companies in the pharmaceutical industry, ADCs present significant growth opportunities. As demand for targeted therapies rises, those who invest in ADC research and development will be at the forefront of innovation. See how the nCounter® ADC Development Panel can help answer complex questions critical for the success of Antibody Drug Conjugates throughout discovery, pre-clinical and clinical development. https://lnkd.in/g7ugBuxZ #Pharmaceuticals #ADCs #Biotechnology #PrecisionMedicine #Innovation #nanostring #nCounter

In a paper newly published in mAbs, Takeda authors thoughtfully discuss the immunogenicity of antibody-based therapeutics as viewed through the lens of T and B cell epitope analyses. From the abstract: By retrospectively examining research involving immunogenicity analysis, we noticed the growing emphasis on elucidating the immunogenic epitope profiles of antibody-based therapeutics aiming for mechanistic understanding the immunogenicity generation and, ideally, mitigating the risks. As such, we have comprehensively summarized here the progress in both experimental and computational methodologies for the characterization of T and B cell epitopes of therapeutics. Furthermore, the successful practice of epitope-driven deimmunization of biotherapeutics is exceptionally highlighted in this article. https://lnkd.in/ezsiFyDZ

Congratulations to Jin-Quan Yu, PhD, the Bristol Myers Squibb Endowed Chair in Chemistry at Scripps Research, for receiving the 2024 Award for Creativity in Molecular Design and Synthesis from the American Chemical Society. Prof. Yu is recognized for his contributions to C-H activation, a transformative approach that has revolutionized molecular design across materials science and pharmaceutical innovation. His methodologies are now integral to drug discovery, with applications spanning cancer therapeutics and acute pain management. More at: https://ow.ly/SyE850TfOp5

REGISTER NOW for ATUM's upcoming Xtalks webinar on uncovering glycosylation's impacts on the quality, activity, and safety of drugs! Learn about the critical role of N- and O-linked glycans in CHO-produced therapeutic proteins and their influence on drug efficacy. Key topics include: 🔬 The role of sialylation in regulating inflammation and immune tolerance 💡 Novel strategies to treat autoimmune diseases using engineered recombinant human IgG1 Fc 🧬 Engineering glycan profiles to improve drug efficacy, half-life, and bioavailability Gain valuable insights from the featured speakers on the future of glycosylation in drug development. ➡️ REGISTER HERE: https://hubs.li/Q02NxHCZ0 Featured speakers: - Bjørn Voldborg, Head of the National Biologics Facility at the Technical University of Denmark (DTU) - Greg Coffey, PhD, Co-Founder & Vice President, Immunology & Clinical Translational Research, Nuvig Therapeutics - Divya Teja Vavilala, PhD, Head of Protein Analytics, ATUM #DrugDevelopment #Antibody #ClinicalResearch #Biotech #Bioengineering